AVXL News and Press, Anavex Life Sciences Corp. From 01/17/24

2024-01-17 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-16 16:46:59 ET More on Anavex Life Sciences Anavex: The Pediatric Rett Trial Failure Is Disastrous How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade)...

Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers Trial to study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX ® 3-7...

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...

2024-01-05 05:17:06 ET Summary Anavex's Alzheimer's trial failed one of its two co-primary endpoints due to a faulty application of statistical analysis. The company's stock nearly doubled after publishing preclinical data on blarcamesine's effects on rats despite its limited rele...

ATLANTA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) complied with federal securities laws. On January 2, 2024, Anavex announced topline results from the phase...

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in their Anavex Life Sciences Corp. investment should contact the firm to learn more about how they m...

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...